HK1257460A1 - 用於免疫疗法的巨噬细胞的遗传工程 - Google Patents

用於免疫疗法的巨噬细胞的遗传工程 Download PDF

Info

Publication number
HK1257460A1
HK1257460A1 HK18116695.4A HK18116695A HK1257460A1 HK 1257460 A1 HK1257460 A1 HK 1257460A1 HK 18116695 A HK18116695 A HK 18116695A HK 1257460 A1 HK1257460 A1 HK 1257460A1
Authority
HK
Hong Kong
Prior art keywords
therapy
methods
tumor microenvironment
tme
modifying
Prior art date
Application number
HK18116695.4A
Other languages
English (en)
Chinese (zh)
Inventor
Courtney Crane
Michael C. Jensen
Kara WHITE MOYES
Nicole Lieberman
Original Assignee
Seattle Children's Hospital (dba Seattle Children's Research Institute)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Children's Hospital (dba Seattle Children's Research Institute) filed Critical Seattle Children's Hospital (dba Seattle Children's Research Institute)
Publication of HK1257460A1 publication Critical patent/HK1257460A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18116695.4A 2015-09-09 2016-09-07 用於免疫疗法的巨噬细胞的遗传工程 HK1257460A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562216224P 2015-09-09 2015-09-09
US62/216,224 2015-09-09
US201662361348P 2016-07-12 2016-07-12
US62/361,348 2016-07-12
PCT/US2016/050552 WO2017044487A1 (en) 2015-09-09 2016-09-07 Genetic engineering of macrophages for immunotherapy

Publications (1)

Publication Number Publication Date
HK1257460A1 true HK1257460A1 (zh) 2019-10-18

Family

ID=58240865

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116695.4A HK1257460A1 (zh) 2015-09-09 2016-09-07 用於免疫疗法的巨噬细胞的遗传工程

Country Status (9)

Country Link
US (3) US10525082B2 (https=)
EP (1) EP3347026A4 (https=)
JP (3) JP6959909B2 (https=)
CN (1) CN108243607A (https=)
AU (1) AU2016318773B2 (https=)
CA (1) CA2997912A1 (https=)
HK (1) HK1257460A1 (https=)
SG (1) SG10201913151TA (https=)
WO (1) WO2017044487A1 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
GB201418965D0 (https=) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
EP3347026A4 (en) 2015-09-09 2019-05-08 Seattle Children's Hospital (DBA Seattle Children's Research Institute) GENEMANIPULATION OF MACROPHAGES FOR IMMUNOTHERAPY
MX2018009542A (es) 2016-02-04 2018-11-09 Zhu Zhenglun Tratamiento y diagnostico de trastornos inflamatorios.
WO2017165813A1 (en) 2016-03-25 2017-09-28 Periphagen, Inc. High-transducing hsv vectors
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3601539A4 (en) * 2017-03-28 2021-01-13 Zhenglun Zhu METHODS OF TREATING NEOPLASIC DISEASES
WO2018191619A1 (en) * 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN118374493A (zh) * 2017-05-17 2024-07-23 西雅图儿童医院（Dba西雅图儿童研究所） 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2019089884A2 (en) * 2017-11-01 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
AU2018370217A1 (en) * 2017-11-17 2020-05-28 Memorial Sloan-Kettering Cancer Center Methods and compositions for alleviating Cytokine Release Syndrome
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
WO2019195420A1 (en) 2018-04-04 2019-10-10 Nant Holding IP, LLC Advanced avartar dendritic cells
TW202322828A (zh) * 2018-04-12 2023-06-16 美商凱特製藥公司 利用腫瘤微環境之特性之嵌合受體ｔ細胞治療
CN108727504B (zh) * 2018-04-16 2021-08-27 泉州向日葵生物科技有限公司 一种ifn与抗pd-l1抗体的融合蛋白及其应用
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
KR102922694B1 (ko) 2018-04-19 2026-02-03 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 유전자 편집을 위한 조성물 및 방법
US12410231B2 (en) 2018-05-07 2025-09-09 Board Of Regents Of The University Of Texas System Natural killer cell products and methods
WO2019222423A1 (en) * 2018-05-15 2019-11-21 The Brigham And Women's Hospital, Inc. Compositions and methods related to tumor cell killers and vaccines
US20210254068A1 (en) * 2018-06-19 2021-08-19 Regents Of The University Of Minnesota Genome engineering primary monocytes
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
CN108823171A (zh) * 2018-07-24 2018-11-16 武汉赛云博生物科技有限公司 一种基因工程细胞及体外高效扩增nk细胞的方法
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
GB201818110D0 (en) * 2018-11-06 2018-12-19 Macrophox Ltd Monocytes for cancer targeting
US20220000921A1 (en) * 2018-11-20 2022-01-06 Innovative Cellular Therapeutics Holdings, Ltd. Modified Cell Expressing Therapeutic Agent and Uses thereof
US20220056479A1 (en) * 2018-12-17 2022-02-24 Cure Genetics Co., Ltd. Method For Delivering Gene In Cells
KR20210122814A (ko) * 2019-02-01 2021-10-12 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 조작된 유전자 발현을 조절하기 위한 미세환경 센서
JP2022524951A (ja) * 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
JP2022531814A (ja) * 2019-03-12 2022-07-12 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ 改変細胞の増幅およびその応用
CA3135165A1 (en) * 2019-03-28 2020-10-01 Sierra Oncology, Inc. Methods of treating cancer with chk1 inhibitors
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
CN110760480B (zh) * 2019-07-09 2021-07-02 杭州师范大学 一种抗肿瘤nk细胞及其制备方法
CN114981409A (zh) 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
WO2021050752A1 (en) * 2019-09-11 2021-03-18 The Board Of Trustees Of The Leland Stanford Junior University Chimeric orthogonal receptor proteins and methods of use
BR112022005044A2 (pt) * 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
WO2021064655A1 (en) * 2019-10-02 2021-04-08 Massachusetts Institute Of Technology High-throughput genetic screening
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CN111150748A (zh) * 2019-12-27 2020-05-15 杭州荣谷生物科技有限公司 重组溶瘤病毒在制备治疗消化道癌药物中的用途
CN111087460B (zh) * 2020-01-14 2021-07-30 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种广谱型抗菌肽及其应用
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
WO2021189008A1 (en) 2020-03-20 2021-09-23 Lyell Immunopharma, Inc. Novel recombinant cell surface markers
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
GB202007906D0 (en) 2020-05-27 2020-07-08 Univ Edinburgh Method of transfecting macrophages
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
EP4161536A4 (en) 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
US20230226181A1 (en) * 2020-06-22 2023-07-20 Nanjing Legend Biotech Co., Ltd. GENETIC ENGINEERING OF gamma delta T CELLS FOR IMMUNOTHERAPY
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
WO2022165260A1 (en) * 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
JP2024527593A (ja) * 2021-07-09 2024-07-25 レジェンド バイオテック アイルランド リミテッド 変異型ｉｌ－１５組成物及びその方法
WO2023053828A1 (ja) * 2021-09-30 2023-04-06 テルモ株式会社 化学療法制御装置、化学療法制御システム、化学療法制御装置の制御方法及び化学療法制御プログラム
US20250000974A1 (en) * 2021-10-27 2025-01-02 The Regents Of The University Of California Combination of human natural killer cells and macrophages for cancer therapy
CN114404600B (zh) * 2022-01-21 2023-06-27 首都医科大学附属北京同仁医院 一种用于治疗肿瘤的药物组合及其应用
CN114657143B (zh) * 2022-03-11 2022-10-25 西安电子科技大学 一种肿瘤微环境调控型car-单核/巨噬细胞及其制备方法和应用
US20250312486A1 (en) * 2022-04-18 2025-10-09 City Of Hope Compositions for restoring mecp2 gene function and methods of use thereof
IL316314A (en) * 2022-04-18 2024-12-01 Candel Therapeutics Inc Compositions and methods for viral vectors
WO2024215990A2 (en) * 2023-04-13 2024-10-17 William Marsh Rice University Regulated cells expressing cytokines
WO2025251079A1 (en) * 2024-05-31 2025-12-04 University Of Massachusetts Rna compositions and methods of use thereof in the treatment of cancer
WO2026062037A1 (en) 2024-09-18 2026-03-26 Myllia Biotechnology Gmbh Gene perturbation in human monocyte-derived macrophages
WO2026069312A1 (en) 2024-09-24 2026-04-02 Yeda Research And Development Co. Ltd. Immune cells expressing an inducible therapeutic agent and uses thereof
CN119020422A (zh) * 2024-10-28 2024-11-26 昆明医科大学 一种稳转萤火虫萤光素酶靶细胞株的构建方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007659A1 (en) 1997-04-17 2001-07-12 The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
US7432351B1 (en) * 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
IL296832A (en) 2005-10-18 2022-11-01 Nat Jewish Health Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US9023648B2 (en) * 2009-12-30 2015-05-05 University Of Massachusetts Method of transducing non-dividing myeloid cells utilizing chimeric murine leukemia viruses containing Vpx
MX374075B (es) * 2010-03-26 2025-03-05 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
US9987308B2 (en) * 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
EP3326467B1 (en) 2011-09-16 2020-03-11 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
CA2861491C (en) * 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US9713635B2 (en) * 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) * 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
AU2013329186B2 (en) * 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
WO2014164544A1 (en) * 2013-03-09 2014-10-09 Baylor College Of Medicine Vascular-targeted t-cell therapy
US9587032B2 (en) * 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
ES2792849T3 (es) 2014-02-10 2020-11-12 Univ Emory Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
IL315940A (en) * 2015-07-28 2024-11-01 Univ Pennsylvania Altered monocytes/macrophages expressing chimeric antigen receptors and their uses
US11352439B2 (en) 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
EP3347026A4 (en) * 2015-09-09 2019-05-08 Seattle Children's Hospital (DBA Seattle Children's Research Institute) GENEMANIPULATION OF MACROPHAGES FOR IMMUNOTHERAPY

Also Published As

Publication number Publication date
US20200155597A1 (en) 2020-05-21
EP3347026A4 (en) 2019-05-08
US20170087185A1 (en) 2017-03-30
WO2017044487A1 (en) 2017-03-16
CA2997912A1 (en) 2017-03-16
US10525082B2 (en) 2020-01-07
SG10201913151TA (en) 2020-03-30
JP2018528774A (ja) 2018-10-04
AU2016318773B2 (en) 2024-08-01
JP7298103B2 (ja) 2023-06-27
AU2016318773A1 (en) 2018-04-12
JP2023109956A (ja) 2023-08-08
CN108243607A (zh) 2018-07-03
EP3347026A1 (en) 2018-07-18
US11826384B2 (en) 2023-11-28
JP6959909B2 (ja) 2021-11-05
US20240091256A1 (en) 2024-03-21
JP2021118723A (ja) 2021-08-12

Similar Documents

Publication Publication Date Title
HK1257460A1 (zh) 用於免疫疗法的巨噬细胞的遗传工程
JP2017525364A5 (https=)
EA202190624A1 (ru) Car-экспрессирующие т-клетки и car-экспрессирующий вектор
PH12016502009A1 (en) Method and compositions for cellular immunotherapy
HK1255161A1 (zh) 用於过继性细胞治疗的工程细胞
MX2023004169A (es) Alteracion de la expresion genetica en celulas t modificadas con el receptor de antigeno quimerico (cart) y usos de las mismas.
NZ731279A (en) Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
EP4257675A3 (en) Delivery of materials to anucleate cells
MX2018010288A (es) Sistema de transposon y metodos de uso.
MY200749A (en) Anti-icos agonist antibodies and uses thereof
PH12018500926A1 (en) EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT ?d T CELLS AND USES OF THESE CELLS
NZ739133A (en) Cellular targeted active ingredient delivery system
MX2019010974A (es) Compuestos y metodos para la reduccion celular especifica de tumor.
MX381908B (es) Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
EP4667492A3 (en) Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
NZ730382A (en) Car expression vector and car-expressing t cells
EP4303232A3 (en) Chimeric antigen receptor and methods of use thereof
WO2016073955A3 (en) Cells lacking b2m surface expression and methods for allogeneic administration of such cells
EP3829561A4 (en) Substituted-3h-imidazo[4,5-c]pyridine and 1h pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (enpp1) and stimulator for interferon genes (sting) modulators as cancer immunotherapeutics
MX379210B (es) Acoplador trifuncional de antígeno de células t y métodos y usos del mismo.
MX2021006932A (es) Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.
WO2016026854A3 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
PH12013500990A1 (en) Neutralizing anti-ccl20 antibodies
NZ710810A (en) Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
MX2018010172A (es) Sistema vector inmunoestimulante novedoso.